Previous close | 8.70 |
Open | 8.70 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 37.50 |
Expiry date | 2024-09-20 |
Day's range | 8.70 - 8.70 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Pfizer stock is now above its 50-day line on better-than-expected first-quarter sales. Is PFE stock a buy now?
The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.